Cannabinoids & the Endocannabinoid System

This page is general educational information only. It is not medical advice and does not recommend the use of any substance. Many cannabinoids are prescription-only or controlled substances in Australia and can only be accessed through a registered medical practitioner. If you have questions about your health, please consult a qualified health practitioner.

Cannabinoids are a class of chemical compounds that interact with a biological signalling network found in the human body. They have become a significant subject of scientific research, and this page explains the underlying biology, the terminology, and the Australian regulatory context in neutral terms. The aim is to help readers understand the vocabulary they may encounter, not to suggest that any cannabinoid is appropriate for any person or purpose.

Cannabinoids are compounds that act on the body's cannabinoid receptors. They are generally grouped into three categories:

• Phytocannabinoids — cannabinoids produced by plants. The most studied are cannabidiol (CBD) and tetrahydrocannabinol (THC).
• Endocannabinoids — cannabinoids produced naturally within the human body.
• Synthetic cannabinoids — compounds made in a laboratory to interact with cannabinoid receptors.

Beyond CBD and THC, plants produce a range of so-called minor cannabinoids, such as cannabigerol (CBG) and cannabinol (CBN). These minor cannabinoids are present in smaller quantities and are, in general, far less studied. Researchers are actively investigating their distinct chemical properties, but the evidence base for most minor cannabinoids remains limited and preliminary.

A useful point of clarity is that the chemistry of a cannabinoid is distinct from its legal classification. Two cannabinoids may be chemically related yet sit in very different regulatory categories, primarily because of differences in their psychoactivity and risk profile. Chemistry and law are related but separate questions.

The endocannabinoid system (ECS) is a signalling network present throughout the human body. It is studied as a regulator of physiological balance, a concept biologists call homeostasis. The ECS has three main components:

• Receptors — the two best-characterised are CB1 and CB2. CB1 receptors are concentrated in the central nervous system, while CB2 receptors are found more in immune tissues and the periphery.
• Endogenous ligands — the body's own cannabinoid molecules, the best known being anandamide and 2-AG, which bind to these receptors.
• Enzymes — proteins that synthesise and break down these endogenous ligands, controlling how long their signals last.

The ECS is described in the scientific literature as a modulatory system: rather than switching processes simply on or off, it tends to fine-tune the activity of other systems. This is one reason the biology is intricate and why simple narratives about cannabinoids often fail to capture the underlying complexity.

Different cannabinoids interact with this system in different ways. THC, for example, binds directly to CB1 receptors, which is associated with its psychoactive properties. CBD interacts with the system through more complex and indirect mechanisms that researchers are still working to fully characterise, and it is also studied for interactions with targets beyond the classical cannabinoid receptors. Describing these mechanisms is a matter of biochemistry; it is not a claim about any health outcome.

In discussions of cannabinoid preparations, three composition terms appear frequently:

• Isolate — a single purified cannabinoid, such as CBD, with other plant compounds removed.
• Broad-spectrum — a preparation containing multiple cannabinoids and other plant compounds, but with THC removed or reduced.
• Full-spectrum — a preparation that retains the broader range of compounds naturally present in the plant, which may include THC.

These terms describe chemical composition only. They are not indicators of quality or of any therapeutic property, and the regulatory status of a preparation depends on its actual constituents — particularly its THC content. A consumer cannot reliably infer the contents of a preparation from marketing language alone, which is part of why testing and regulated supply chains matter.

Cannabis and many other plants also produce terpenes, aromatic compounds responsible for characteristic scents. Some researchers have proposed that cannabinoids and terpenes might interact to influence each other's biological activity, an idea often called the entourage effect. It is important to frame this accurately: the entourage effect is a hypothesis that is still under scientific study, not an established fact. The evidence to date is mixed and largely preliminary, and the question of whether, and to what degree, such interactions occur in humans remains open. Some laboratory findings are consistent with the idea, while other studies have not found the effects predicted by it. Neutral educational sources therefore present it as an area of ongoing investigation rather than a settled conclusion, and caution against using the concept to make confident claims.

Bioavailability refers to the proportion of a substance that reaches systemic circulation and the rate at which it does so. It is a core concept in pharmacology and a practical challenge for many cannabinoids, which are fat-soluble (lipophilic) and not easily absorbed in their raw form.

The way a substance is formulated and administered affects its bioavailability. Oral preparations are subject to first-pass metabolism in the liver, which can reduce how much of the compound reaches circulation, and absorption can also vary depending on whether a preparation is taken with food. Other routes of administration follow different absorption patterns and time courses. Researchers and formulation scientists study techniques intended to improve the consistency and predictability of absorption, since variable absorption makes both research and clinical use harder to manage.

These are technical pharmaceutical considerations and are described here purely to explain the science, not to suggest any product or use. The practical implication is simply that the form a substance takes is not a trivial detail; it materially affects how the substance behaves in the body, which is one more reason such matters belong with a qualified practitioner.

Because cannabis preparations are chemically complex, researchers place considerable emphasis on knowing exactly what is in a given product. A preparation may contain a defined ratio of CBD to THC, a spread of minor cannabinoids, and an array of terpenes, all of which can vary between plants and batches. Reproducible science depends on being able to characterise and control this composition.

This is also why analytical testing matters. In a regulated context, products are tested to confirm cannabinoid content and to screen for contaminants such as pesticides, solvents, heavy metals and microbial impurities. Preparations obtained outside a regulated supply chain are not subject to such testing, so their actual contents cannot be verified — a point that neutral educational and regulatory sources consistently stress. None of this should be read as a claim about effects; it is a description of how quality and consistency are approached scientifically.

In Australia, cannabis-derived cannabinoids are scheduled substances. Depending on the cannabinoid and its concentration, they are typically Schedule 4 (prescription-only) or Schedule 8 (controlled). This means they can only be lawfully accessed through a registered medical practitioner, and most are not entered as registered products on the ARTG.

Where a suitable registered product is unavailable, access may occur through pathways administered by the TGA, such as the Special Access Scheme or the Authorised Prescriber Scheme. Patients cannot self-prescribe these substances, and products obtained outside the regulated system fall outside any quality assurance. Any question about whether such a substance is appropriate for an individual must be directed to a qualified health practitioner. This page remains general information only.